Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Pharmacogenomics in pediatric leukemia.

Paugh SW, Stocco G, Evans WE.

Curr Opin Pediatr. 2010 Dec;22(6):703-10. doi: 10.1097/MOP.0b013e32833fde85. Review.

2.

Pharmacogenomics of childhood acute lymphoblastic leukemia.

Brenner TL, Pui CH, Evan WE.

Curr Opin Mol Ther. 2001 Dec;3(6):567-78. Review.

PMID:
11804271
3.

Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia.

Pui CH, Relling MV, Evans WE.

Best Pract Res Clin Haematol. 2002 Dec;15(4):741-56. Review.

PMID:
12617874
4.

Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy.

Relling MV, Ramsey LB.

Hematology Am Soc Hematol Educ Program. 2013;2013:126-30. doi: 10.1182/asheducation-2013.1.126. Review.

PMID:
24319173
5.

Pharmacogenetics in acute lymphoblastic leukemia.

Cheok MH, Pottier N, Kager L, Evans WE.

Semin Hematol. 2009 Jan;46(1):39-51. doi: 10.1053/j.seminhematol.2008.09.002. Review.

6.

Pharmacogenomics of acute lymphoblastic leukemia.

Kager L, Evans WE.

Curr Opin Hematol. 2006 Jul;13(4):260-5. Review.

PMID:
16755223
8.

Pharmacogenetics of acute lymphoblastic leukemia treatment response.

Cunningham L, Aplenc R.

Expert Opin Pharmacother. 2007 Oct;8(15):2519-31. Review.

PMID:
17931087
9.

Genetic studies in acute lymphoblastic leukemia.

Pui CH.

Acta Paediatr Taiwan. 2000 Nov-Dec;41(6):303-7. Review.

PMID:
11198935
10.

Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.

Cheok MH, Evans WE.

Nat Rev Cancer. 2006 Feb;6(2):117-29. Review. Erratum in: Nat Rev Cancer. 2006 Mar;6(3):249.

PMID:
16491071
11.

Pharmacogenomics of acute leukemia.

Ansari M, Krajinovic M.

Pharmacogenomics. 2007 Jul;8(7):817-34. doi: 10.2217/14622416.8.7.817. Review.

PMID:
18240908
12.
13.

Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.

Davidsen ML, Dalhoff K, Schmiegelow K.

J Pediatr Hematol Oncol. 2008 Nov;30(11):831-49. doi: 10.1097/MPH.0b013e3181868570. Review.

PMID:
18989161
14.

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.

Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH.

N Engl J Med. 1998 Feb 19;338(8):499-505.

15.

Personalized medicine in pediatric cardiology: do little changes make a big difference?

Manickaraj AK, Mital S.

Curr Opin Pediatr. 2012 Oct;24(5):584-91. doi: 10.1097/MOP.0b013e328357a4ea. Review.

PMID:
22890065
16.

The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate.

Niedzielska E, Węcławek-Tompol J, Matkowska-Kocjan A, Chybicka A.

Adv Clin Exp Med. 2013 Jul-Aug;22(4):579-84. Review.

17.

Childhood acute lymphoblastic leukemia.

Pui CH, Relling MV, Campana D, Evans WE.

Rev Clin Exp Hematol. 2002 Jun;6(2):161-80; discussion 200-2.

PMID:
12196214
18.

Ontogeny and drug metabolism in newborns.

Dotta A, Chukhlantseva N.

J Matern Fetal Neonatal Med. 2012 Oct;25 Suppl 4:83-4. doi: 10.3109/14767058.2012.715463. Review.

PMID:
22958028
19.

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.

Dulucq S, Laverdière C, Sinnett D, Krajinovic M.

Expert Opin Drug Metab Toxicol. 2014 May;10(5):699-719. doi: 10.1517/17425255.2014.893294. Review.

PMID:
24673379
20.

Pharmacogenetics, pharmacogenomics, and individualized medicine.

Ma Q, Lu AY.

Pharmacol Rev. 2011 Jun;63(2):437-59. doi: 10.1124/pr.110.003533. Review.

Items per page

Supplemental Content

Support Center